226 related articles for article (PubMed ID: 27111172)
21. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
Ho CM; Lee CH; Lee MC; Zhang JF; Wang JY; Hu RH; Lee PH
BMC Cancer; 2018 Apr; 18(1):401. PubMed ID: 29631561
[TBL] [Abstract][Full Text] [Related]
22. Association between renin-angiotensin-aldosterone system blockade and clinical outcomes in patients with hypertension: real-world observation from a nationwide hypertension cohort.
Park CS; Kim B; Rhee TM; Lee HJ; Lee HS; Park JB; Kim YJ; Han KD; Kim HK
Clin Res Cardiol; 2023 Nov; 112(11):1577-1586. PubMed ID: 36867200
[TBL] [Abstract][Full Text] [Related]
23. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
24. Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis.
Al-Mallah M; Khawaja O; Sinno M; Alzohaili O; Samra AB
Cardiol J; 2010; 17(5):448-56. PubMed ID: 20865674
[TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials.
Lakhdar R; Al-Mallah MH; Lanfear DE
J Card Fail; 2008 Apr; 14(3):181-8. PubMed ID: 18381180
[TBL] [Abstract][Full Text] [Related]
26. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis.
Tandon P; Abraldes JG; Berzigotti A; Garcia-Pagan JC; Bosch J
J Hepatol; 2010 Aug; 53(2):273-82. PubMed ID: 20570385
[TBL] [Abstract][Full Text] [Related]
27. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
[TBL] [Abstract][Full Text] [Related]
28. When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes.
Lemley KV
Pediatr Nephrol; 2010 Oct; 25(10):2021-34. PubMed ID: 20352458
[TBL] [Abstract][Full Text] [Related]
29. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Zeller A; Battegay E
Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
[TBL] [Abstract][Full Text] [Related]
30. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
Lip GY; Frison L; Grind M
J Intern Med; 2007 Jun; 261(6):577-86. PubMed ID: 17547713
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
32. ACE inhibitor-angiotensin receptor blocker combinations: a clinician's perspective.
Doulton TW
Mini Rev Med Chem; 2006 May; 6(5):491-7. PubMed ID: 16719821
[TBL] [Abstract][Full Text] [Related]
33. Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland.
Wan Md Adnan WA; Zaharan NL; Bennett K; Wall CA
Br J Clin Pharmacol; 2011 Mar; 71(3):458-66. PubMed ID: 21284706
[TBL] [Abstract][Full Text] [Related]
34. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.
Maione A; Navaneethan SD; Graziano G; Mitchell R; Johnson D; Mann JF; Gao P; Craig JC; Tognoni G; Perkovic V; Nicolucci A; De Cosmo S; Sasso A; Lamacchia O; Cignarelli M; Manfreda VM; Gentile G; Strippoli GF
Nephrol Dial Transplant; 2011 Sep; 26(9):2827-47. PubMed ID: 21372254
[TBL] [Abstract][Full Text] [Related]
35. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A Network Meta-Analysis.
Luo X; Xu J; Zhou S; Xue C; Chen Z; Mao Z
Clin J Am Soc Nephrol; 2023 Aug; 18(8):1019-1030. PubMed ID: 37256921
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population--a nationwide cohort study.
Hsu CY; Huang CC; Chan WL; Huang PH; Chiang CH; Chen TJ; Chung CM; Lin SJ; Chen JW; Leu HB
Circ J; 2013; 77(2):405-10. PubMed ID: 23149416
[TBL] [Abstract][Full Text] [Related]
37. Submaximal Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dosing Among Persons With Proteinuria.
Chu CD; Powe NR; Estrella MM; Shlipak MG; McCoy IE; Tuot DS
Mayo Clin Proc; 2022 Nov; 97(11):2099-2106. PubMed ID: 36210196
[TBL] [Abstract][Full Text] [Related]
38. Association between RAAS Antagonism and COVID-19-related Mortality in Patients with Overweight/Obesity-related Hypertension: A Retrospective Cohort Study.
Shams E; Kamalumpundi V; Cheng L; Taiwo A; Shibli-Rahhal A; Dokun AO; Correia MLG
Arq Bras Cardiol; 2023 Mar; 120(4):e20220277. PubMed ID: 37098985
[TBL] [Abstract][Full Text] [Related]
39. Prescription drug benefits and use of guideline recommended medications by elderly Medicare beneficiaries with diabetes mellitus.
Tjia J; Briesacher BA
J Am Geriatr Soc; 2008 Oct; 56(10):1879-86. PubMed ID: 18771456
[TBL] [Abstract][Full Text] [Related]
40. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a medicaid managed care organization.
Cooke CE; Fatodu H
J Manag Care Pharm; 2006 Oct; 12(8):649-55. PubMed ID: 17269843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
